Gold prices hold sharp gains as soft US jobs data fuels Fed rate cut bets
SOUTH SAN FRANCISCO - CERo Therapeutics Holdings, Inc. (NASDAQ:CERO), a company specializing in engineered T cell immunotherapies with a current market capitalization of $1.6 million, has announced the allowance of two significant patent applications by the U.S. Patent and Trademark Office (USPTO). These allowances, granted in March 2025, strengthen the company's intellectual property position regarding its lead compound CER-1236, a potential cancer treatment. According to InvestingPro analysis, while the company holds more cash than debt on its balance sheet, it currently trades below its Fair Value.
The first allowed patent application, No. 17/040,472, covers the composition and methods of use for CER-1236, which combines a phosphatidylserine-targeting CD4+ CER-T cell with either a CD8+ CAR-T cell or a CD8+ recombinant TCR-T cell for cancer treatment. This Notice of Allowance is a step towards the issuance of a U.S. patent, pending completion of administrative procedures. Despite recent patent developments, InvestingPro data shows the stock has experienced significant volatility, with a 91% decline over the past six months, though it has shown signs of recovery with a 20% gain in the past week.
The second Notice of Allowance, for Patent Application No. 17/040,317, pertains to the design aspects of CER-1236, specifically for a chimeric TIM4 receptor that includes a TIM4 binding domain and canonical T cell signaling domains. This patent is expected to provide composition of matter protection.
With these developments, CERo's intellectual property now encompasses nine patent families, with protection extending to 2039 in the United States. The company's portfolio is supported by 17 issued patents and allowed patent applications internationally.
Chris Ehrlich, CEO of CERo Therapeutics, expressed the significance of these allowances for the company's market presence, noting the novelty of their approach in potentially treating cancer. The company is preparing for clinical trials, with its lead product candidate, CER-1236, anticipated to enter trials in 2025 for hematological malignancies.
CERo's proprietary platform aims to merge characteristics of both innate and adaptive immunity into a single therapeutic construct. The company's Chimeric Engulfment Receptor T cells (CER-T) are designed to redirect patient-derived T cells to eliminate tumors by employing phagocytic mechanisms to destroy cancer cells. This approach is believed to have a broader therapeutic application than current CAR-T cell therapies, potentially addressing both hematological malignancies and solid tumors.
This news comes as CERo prepares to initiate human trials for ovarian and non-small cell lung cancers, following the clearance of its Investigational New Drug (IND) application and the announcement of its initial trial site for a Phase 1 trial in Acute Myeloid Leukemia (AML). With an overall Financial Health Score rated as 'WEAK' by InvestingPro, investors should closely monitor the company's upcoming earnings report scheduled for April 9, 2025. InvestingPro subscribers have access to 12 additional key insights about CERO's financial position and market performance.
The information in this article is based on a press release statement from CERo Therapeutics Holdings, Inc.
In other recent news, CERo Therapeutics Holdings, Inc. has received FDA approval to begin a Phase 1 clinical trial for its lead compound, CER-1236, aimed at treating advanced solid tumors such as non-small cell lung cancer and ovarian cancer. The company has also announced a partnership with the University of California Davis to produce CER-1236 for a Phase 1 trial targeting Acute Myeloid Leukemia (AML), with patient dosing expected to start in the first half of 2025. Additionally, an amendment to CERo's Investigational New Drug application has been positively reviewed by the FDA, streamlining the manufacturing timeline by about a week. CERo plans to present an abstract at the American Society of Clinical Oncology's annual conference, which will provide further updates on its program development. Promising preclinical results for CER-1236 were reported, showing effective treatment of ovarian cancer cells in animal models without toxicity. These developments reflect CERo's ongoing efforts to advance its immunotherapy platform, which integrates features of innate and adaptive immunity. The company's proprietary Chimeric Engulfment Receptor T cells (CER-T) are designed to engage the immune system to eliminate tumors. CERo's CEO, Chris Ehrlich, highlighted the company's commitment to avoiding pre-trial delays by collaborating closely with partners.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.